✨ Free AI Report
Synaptogenix, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Synaptogenix, Inc.
Research Preview

Synaptogenix, Inc.: Business Overview, Financials & Competitive Analysis

Synaptogenix is a developer of regenerative therapeutics for neurodegenerative diseases and developmental disorders. Founded in 2012, the company is publicly traded and leverages Bryostatin-1 and its analogues for the...

Analyst-debate audio for Synaptogenix, Inc.

AskCyborg analysts argue the bull and bear cases for Synaptogenix, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Synaptogenix, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Clinical-stage biotech company with failed lead program but strong cash position, currently executing a strategic transformation...

Read the full analyst-debate transcript →
Industry Neurodegenerative disease therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 22, 2026
AI-Verified Research
30+ Page Report

Get the Latest Synaptogenix, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Synaptogenix, Inc. Overview

Pro stress-test →

Synaptogenix is a developer of regenerative therapeutics for neurodegenerative diseases and developmental disorders. Founded in 2012, the company is publicly traded and leverages Bryostatin-1 and its analogues for therapeutic development.

Strategic Profile

Pro stress-test →

As of December 2024, the company's Board formed a Special Committee to explore strategic opportunities to create and enhance value for investors. In June 2025, the company rebranded to TAO Synergies Inc. and shifted its strategic focus, with the common stock beginning to trade under the new ticker symbol TAOX on or about July 1, 2025. The company is exploring various alternatives to its previous research and development programs while expecting a dramatic decline in its cash burn rate.

Competitive Landscape

Pro stress-test →

Top competitors include Merck, Roivant Sciences, and Recursion. The company's pipeline focuses on synaptogenic treatment approaches for serious neurodegenerative conditions including Alzheimer's disease, Fragile X Syndrome, MS, Parkinsons, Traumatic Brain Injury, Stroke, and Autism Spectrum Disorders.

Industry Context

Synaptogenix, Inc. operates in Neurodegenerative disease therapeutics.

Key facts

Founded: 2012 · Headquarters: New York, US · Employees: 5-25 · Revenue: N/A · Market cap: $38.5M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Synaptogenix, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Synaptogenix, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Neurodegenerative Disease TherapeuticsLarge pharma with neuroscience programs→Drug Development PlatformClinical-stage biotech company→AI-Driven Drug DiscoveryAI-enabled drug discovery platform→

Compare Synaptogenix, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Synaptogenix, Inc. operates in Neurodegenerative disease therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Neurodegenerative disease therapeutics research →
NEW · MCP server

Ask your AI assistant about Synaptogenix, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Synaptogenix, Inc. and its top competitor on Cyborg Score”
“What did Synaptogenix, Inc. do this quarter?”
“Is Synaptogenix, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Synaptogenix, Inc. do?+
Synaptogenix is a developer of regenerative therapeutics for neurodegenerative diseases and developmental disorders. Founded in 2012, the company is publicly traded and leverages Bryostatin-1 and its analogues for the...
What is Synaptogenix, Inc.'s Cyborg Score?+
Synaptogenix, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Synaptogenix, Inc.'s main competitors?+
Named competitors include Neurodegenerative Disease Therapeutics, Drug Development Platform, AI-Driven Drug Discovery. The full competitive landscape is in the AskCyborg report.
How can I get the full Synaptogenix, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Synaptogenix, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Synaptogenix, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Dave Inc.9nVent Electric plc9Elbit Systems Ltd.9Vertiv Holdings Co9Barrick Mining Corporation9GE Vernova Inc.9Applied Materials, Inc.9Eli Lilly and Company9Microsoft Corporation8Dätwyler Holding AG8Cingulate Inc.8Tristel plc8cBrain8Electrovaya Inc.8Kits Eyecare Ltd.8Sukoon Insurance8Lumax Industries Limited8Tanla Platforms Limited